Literature DB >> 27824767

Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.

Julia C Gage1, William C Hunt, Mark Schiffman, Hormuzd A Katki, Li A Cheung, Orrin Myers, Jack Cuzick, Nicolas Wentzensen, Walter Kinney, Philip E Castle, Cosette M Wheeler.   

Abstract

OBJECTIVE: To compare the risks of histologic high-grade cervical intraepithelial neoplasia (CIN) or worse after different cervical cancer screening test results between two of the largest U.S. clinical practice research data sets.
METHODS: The New Mexico Human Papillomavirus (HPV) Pap Registry is a statewide registry representing a diverse population experiencing varied clinical practice delivery. Kaiser Permanente Northern California is a large integrated health care delivery system practicing routine HPV cotesting since 2003. In this retrospective cohort study, a logistic-Weibull survival model was used to estimate and compare the cumulative 3- and 5-year risks of histologic CIN 3 or worse among women aged 21-64 years screened in 2007-2011 in the New Mexico HPV Pap Registry and 2003-2013 in Kaiser Permanente Northern California. Results were stratified by age and baseline screening result: negative cytology, atypical squamous cells of undetermined significance (ASC-US) (with or without HPV triage), low-grade squamous intraepithelial lesion, and high-grade squamous intraepithelial lesion.
RESULTS: There were 453,618 women in the New Mexico HPV Pap Registry and 1,307,528 women at Kaiser Permanente Northern California. The 5-year CIN 3 or worse risks were similar within screening results across populations: cytology negative (0.52% and 0.30%, respectively, P<.001), HPV-negative and ASC-US (0.72% and 0.49%, respectively, P=.5), ASC-US (3.4% and 3.4%, respectively, P=.8), HPV-positive and ASC-US (7.7% and 7.1%, respectively, P=.3), low-grade squamous intraepithelial lesion (6.5% and 5.4%, respectively, P=.009), and high-grade squamous intraepithelial lesion (53.1% and 50.4%, respectively, P=.2). Cervical intraepithelial neoplasia grade 2 or worse risks and 3-year risks had similar trends across populations. Age-stratified analyses showed more variability, especially among women aged younger than 30 years, but patterns of risk stratification were comparable.
CONCLUSION: Current U.S. cervical screening and management recommendations are based on comparative risks of histologic high-grade CIN after screening test results. The similar results from these two large cohorts from different real-life clinical practice settings support risk-based management thresholds across U.S. clinical populations and practice settings.

Entities:  

Mesh:

Year:  2016        PMID: 27824767      PMCID: PMC5247269          DOI: 10.1097/AOG.0000000000001721

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  Transitioning from HPV 101 to HPV 202.

Authors:  Warner K Huh; Richard Guido
Journal:  Am J Obstet Gynecol       Date:  2017-03       Impact factor: 8.661

2.  Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.

Authors:  Ming Guo; Abha Khanna; Jianping Wang; Marilyn A Dawlett; Teresa L Kologinczak; Genevieve R Lyons; Roland L Bassett; Nour Sneige; Yun Gong; Therese B Bevers
Journal:  Cancer Cytopathol       Date:  2017-05-12       Impact factor: 5.284

3.  Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix.

Authors:  Carolann Risley; Megan A Clarke; Kim R Geisinger; Mary W Stewart; Lei Zhang; Kim W Hoover; Laree M Hiser; Kenyata Owens; Maria DeMarco; Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Cytopathol       Date:  2020-04-03       Impact factor: 5.284

4.  Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.

Authors:  Anja Oštrbenk Valenčak; Anja Šterbenc; Katja Seme; Mario Poljak
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

5.  Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Authors:  Maria Demarco; Thomas S Lorey; Barbara Fetterman; Li C Cheung; Richard S Guido; Nicolas Wentzensen; Walter K Kinney; Nancy E Poitras; Brian Befano; Philip E Castle; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2017-10       Impact factor: 1.925

6.  Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort.

Authors:  Jesper Bonde; Fabio Bottari; Valentin Parvu; Helle Pedersen; Karen Yanson; Anna D Iacobone; Salma Kodsi; Fabio Landoni; Laurence Vaughan; Ditte M Ejegod; Maria T Sandri
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

7.  Hispanic Ethnicity and Cervical Cancer Precursors Among Low-Income Women in Arizona.

Authors:  Sally L Riggs; Cynthia A Thomson; Elizabeth Jacobs; Chistina A Cutshaw; John E Ehiri
Journal:  Int J Womens Health       Date:  2021-10-19

8.  STRIDES - STudying Risk to Improve DisparitiES in Cervical Cancer in Mississippi - Design and baseline results of a Statewide Cohort Study.

Authors:  Carolann Risley; Mary W Stewart; Kim R Geisinger; Laree M Hiser; Jody C Morgan; Kenyata J Owens; Krishna Ayyalasomayajula; Rhonda M Rives; Ashish Jannela; Dianne E Grunes; Lei Zhang; Mark Schiffman; Nicolas Wentzensen; Megan A Clarke
Journal:  Prev Med       Date:  2021-07-20       Impact factor: 4.018

9.  HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.

Authors:  Mark H Stoler; Thomas C Wright; Valentin Parvu; Karen Yanson; Karen Eckert; Salma Kodsi; Charles Cooper
Journal:  Am J Clin Pathol       Date:  2019-03-01       Impact factor: 2.493

10.  2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation.

Authors:  Li C Cheung; Didem Egemen; Xiaojian Chen; Hormuzd A Katki; Maria Demarco; Amy L Wiser; Rebecca B Perkins; Richard S Guido; Nicolas Wentzensen; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2020-04       Impact factor: 3.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.